Autoimmune diseases which follow allogeneic BMT from a donor who is a patient or a carrier of an autoimmune condition are considered to be a paradigm of adoptive autoimmunity. Seven cases of autoimmune thyroiditis associated with clinical hyperthyroidism have been published to date. In the case reported here a 35-year-old female patient with AML of the M2 subtype received unmanipulated PBSC from her HLA-identical sister who had therapeutically controlled Graves' disease. Antithyroid antibodies, including thyrotropin receptor (TSHR) antibodies, appeared 1 year after transplant. Clinical hyperthyroidism requiring thyrostatic medication appeared after 2 years. The biological and clinical implications of adoptive, post-transplant autoimmunity are briefly discussed.
The definition of adoptive autoimmunity has been proposed for the transfer of an autoimmune state from a haematologically normal donor with an autoimmune condition to a recipient with a severe disease of the blood but with no (apparent) autoimmune phenomena. 1 This etiopathogenesis was first discovered and established experimentally, 2 but was subsequently reported also in the area of clinical transplantation. 1, 3 However, the emergence of post-BMT autoimmune phenomena do not always require the transfer of pathogenic lymphoid clones from donor to recipient, and it has been argued that most of the autoimmune events occurring after BMT result from an immunological dysregulation state ('immunological chaos'). 3, 4 Only direct transfer of pathogenic lymphoid clones of varying differentiation from donor to recipient is a clear example of post-transplant adoptive autoimmunity.
Adoptive, transplanted autoimmune diseases (AID) include predominantly organ-specific conditions such as thyroid disease, insulin-dependent diabetes (IDDM), myasthenia gravis (a special situation), celiac disease and auto-immune cytopenias. Hypothyroid complications may be multifactorial in aetiology, 3 and are of little interest to this report. Post-transplant adoptive hyperthyroidism is rarer: seven case reports have been published to date and are summarized by Karthaus et al. 5 In one case the transfer of postulated antithyroid donor lymphocytes caused severe immune hyperthyroidism following transplantation of allogeneic CD34
+ positively selected peripheral blood cells. 5 We report an additional case in which the recipient, a euthyroid, 35-year-old female with AML of the M2 subtype, received T-replete PBSC from her HLA-identical sister who had clinical Graves' disease (GD), developed anti-thyroid antibodies 1 year after BMT, and went on to express anti-TSH-R antibodies and clinical hyperthyroidism 2 years post transplant.
Case report

Donor
A 42-year-old (at the time of transplant) woman was diagnosed as having Graves' disease (GD) in 1986. She had complained of fatigue, irritability, tremors and weight loss, showed abnormal values of thyroid hormones (FT4 44.5 pg/ml, TSH 0.01 mU/ml), and had high antithyreoperoxidase antibodies (TPO Ab): 7357 U/ml. She was treated with metimazole for 6 years, after which treatment was discontinued. In May, 1996 she had a small firm goitre, exophthalmos and tachycardia (100/min at rest). TSH was Ͻ0.002 mU/ml, and TPO Ab were Ͼ5000 U/ml. She was treated with metimazole until all clinical signs and symptoms subsided and normal ranges of thyroid hormones were present. After having reached a euthyroid state she was given G-CSF 10 mg/kg for 5 days, and then PBSC were collected by leukapheresis. No TCD was performed.
Patient
In 1995 this 35-year-old woman (UPN 941) was diagnosed as having acute myeloblastic leukaemia of the M2 FAB subtype. She had 15% leukemic blasts in the BM aspirate, and a normal karyotype was reported. She was treated with three courses of the ICE regimen (idarubicin, cytarabine and etoposide). On 1 April 1996 CR was achieved, and maintained. In August 1996 she underwent allogeneic PBSC transplantation (6.2 × 10 8 mononuclear cells/per kilogram recipient body weight) after conditioning with TBI (990 cGy) and CY (120 mg/kg). The donor was her HLAidentical sister (A2, A26, B8, B38, DR3). Mild (grade I-II) skin GVHD developed, and responded to 6-MP and CsA. She is currently still in CR with complete engraftment. She was euthyroid, both clinically and immunologically, before transplant. One year later she had detectable levels of thyroglobulin antibodies (TG Ab), thyroid peroxidase antibodies (TPO Ab), and just detectable thyrotropin receptor antibodies (THSR Ab). Two years post transplant she had a small but distinctly palpable goitre, clinical hyperthyroidism and high levels of thyroid hormones and antibodies, particularly TSHR Ab (Table 1) . She is currently being treated with metimazole, 10 mg/day.
Discussion
Similarly to post-transplant adoptive IDDM, in which the evolution from the development of islet cell antibodies (ICA) to overt clinical diabetes can be monitored, 6 the appearance of thyrotropin receptor (TSHR) antibodies could be detected in this patient 1 year before the emergence of clinical hyperthyroidism requiring thyrostatic therapy. While some TSHR antibodies stimulate the thyroid, others are inhibitory. In this case it appears that thyroid stimulating antibodies (TSAb) occurred, which are the direct cause of hyperthyroidism in GD, as is demonstrated in neonatal GD, when passive transfer of TSAb causes the fetus and neonate to be hyperthyroid for several weeks after delivery. 7 Thus, GD is considered to be an antibodymediated disorder with a direct relationship to the presence and amount of TSAb. 7 In the case of adoptive, post-BMT autoimmune hyperthyroidism, however, the temporary quiescence indicates cellular transfer with subsequent antibody production. A number of clinical AIDs have been transferred into SCID mice by means of xenogeneic human lymphocytes. They include autoimmune thyroiditis (both of the Hashimoto and Graves' type), primary biliary cirrhosis, pemphigus vulgaris and rheumatoid arthritis. 8 More recently, human autoimmunity has been passed to SCID mice transplanted with thyroid tissue and BM from human GD patients. 9 In conclusion, the concept of adoptive autoimmune hyperthyroidism is reasonable, although other factors such as disruption of regulatory mechanisms 3 must also be considered. It is of interest that autoimmunity was not transferred to recipients of unmanipulated marrow from HLAidentical donors with rheumatoid arthritis and systemic lupus erythematosus, respectively. 10 It has been proposed that fundamental differences in pathophysiology may account for the apparent transfer by BMT of organ-specific diseases and not (to date) of systemic rheumatic AD. 10 The existence of therapeutically controlled AD in a SC donor does not contraindicate BMT for the donor-recipient pair, but requires attentive immunological monitoring.
